JOHNSON & JOHNSON is 344.2x more valuable than Viridian Therapeutics, Inc.DE by market capitalization ($573.71 B vs $1.67 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | VRDN | JNJ |
|---|---|---|
| Market cap | $1.67 B | $573.71 B |
| US-listed rank | #2250 | #20 |
| Revenue (latest FY) | $70.85M | $94.19B |
| Net income (latest FY) | -$342.60M | $26.80B |
| Net margin | -483.6% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 794 | 984 |
JOHNSON & JOHNSON is 344.2x more valuable than Viridian Therapeutics, Inc.DE by market capitalization ($573.71 B vs $1.67 B).
In their latest fiscal years, Viridian Therapeutics, Inc.DE reported $70.85M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Viridian Therapeutics, Inc.DE and JOHNSON & JOHNSON, or browse the full rankings.